{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:41:39Z","timestamp":1777927299918,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) is a recently approved single-tablet antiretroviral regimen and is recommended as a first-line agent. No cases of gynecomastia were reported in clinical trials. We report development of ultrasound-confirmed gynecomastia in a previously antiretroviral-na\u00efve patient approximately two months after starting BIC\/FTC\/TAF, which resolved ten weeks after discontinuing bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) based therapy.<\/jats:p>","DOI":"10.1177\/0956462419895665","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T01:48:58Z","timestamp":1581385738000},"page":"380-382","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of gynecomastia following initiation of bictegravir\/emtricitabine\/tenofovir alafenamide"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5190-0066","authenticated-orcid":false,"given":"MJ","family":"Biagi","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Rockford, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CA","family":"Schriever","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago, Rockford, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-4391","authenticated-orcid":false,"given":"TD","family":"Chiampas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Pharmacotherapy Section, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1182-7997","authenticated-orcid":false,"given":"SM","family":"Michienzi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Pharmacotherapy Section, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MC","family":"Patel","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JD","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, The Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ME","family":"Badowski","sequence":"additional","affiliation":[{"name":"Infectious Diseases Pharmacotherapy Section, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"bibr1-0956462419895665","unstructured":"Biktarvy (package insert). Foster City, CA: Gilead Sciences, Inc. 2019."},{"key":"bibr2-0956462419895665","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2019). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services, https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf (accessed 14 July 2019)."},{"key":"bibr3-0956462419895665","doi-asserted-by":"publisher","DOI":"10.1086\/368314"},{"key":"bibr4-0956462419895665","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-016-0121-z"},{"key":"bibr5-0956462419895665","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/135965350400900416","volume":"9","author":"Mira JA","year":"2004","journal-title":"Antivir Ther"},{"key":"bibr6-0956462419895665","unstructured":"U.S. Food and Drug Administration (2018). Drug approval package: BIKTARVY (bictegravir, emtricitabine, tenofovir alafenamide) tablets, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210251Orig1s000MultidisciplineR.pdf (accessed 14 July 2019)."},{"key":"bibr7-0956462419895665","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS): latest quarterly data files, https:\/\/www.fda.gov\/drugs\/fda-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files (2018, accessed 24 July 2019)."},{"key":"bibr8-0956462419895665","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr9-0956462419895665","doi-asserted-by":"publisher","DOI":"10.1111\/j.1075-122X.2004.21392.x"},{"key":"bibr10-0956462419895665","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2010.00831.x"},{"key":"bibr11-0956462419895665","doi-asserted-by":"publisher","DOI":"10.1258\/0956462021924514"},{"key":"bibr12-0956462419895665","doi-asserted-by":"publisher","DOI":"10.1007\/BF01533381"},{"key":"bibr13-0956462419895665","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0060139"},{"key":"bibr14-0956462419895665","first-page":"405","volume":"15","author":"Psichogiou M","year":"2017","journal-title":"Curr HIV Res"},{"key":"bibr15-0956462419895665","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283511e91"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462419895665","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0956462419895665","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0956462419895665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:40:15Z","timestamp":1777675215000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0956462419895665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1177\/0956462419895665"],"URL":"https:\/\/doi.org\/10.1177\/0956462419895665","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]}}}